دورية أكاديمية
The CHRONOS Real-World Evidence of Biologic Treatments in Psoriatic Arthritis in Italy: A Post Hoc Gender Analysis
| العنوان: | The CHRONOS Real-World Evidence of Biologic Treatments in Psoriatic Arthritis in Italy: A Post Hoc Gender Analysis |
|---|---|
| المؤلفون: | Delia Colombo, Micol Frassi, Giuseppa Pagano Mariano, Enrico Fusaro, Claudia Lomater, Patrizia Del Medico, Florenzo Iannone, Rosario Foti, Massimiliano Limonta, Antonio Marchesoni, Bernd Raffeiner, Ombretta Viapiana, Marco Di Carlo, Rosa Daniela Grembiale, Giuliana Guggino, Paola Faggioli, Enrico Tirri, Roberto Perricone, Pier Carlo Sarzi Puttini, Salvatore De Vita, Fabrizio Conti, Sara Rizzoli, Barbara Roncari, Martina Fiocchi, Roberto Orsenigo, Emanuela Zagni, Collaboration group, Frassi Micol, Caminiti Maurizio, Fusaro Enrico, Lomater Claudia, Del Medico Patrizia, Iannone Fiorenzo, Foti Rosario, Limonta Massimiliano, Marchesoni Antonio, Raffeiner Bernd, Viapiana Ombretta, Grassi Walter, Grembiale Rosa Daniela, Guggino Giuliana, Mazzone Antonino, Tirri Enrico, Perricone Roberto, Sarzi Puttini Pier Carlo, De Vita Salvatore, Conti Fabrizio |
| المصدر: | Women's Health Reports, Vol 3, Iss 1, Pp 162-171 (2022) |
| بيانات النشر: | Mary Ann Liebert, 2022. |
| سنة النشر: | 2022 |
| المجموعة: | LCC:Gynecology and obstetrics LCC:Public aspects of medicine |
| مصطلحات موضوعية: | biologics, effectiveness, gender differences, psoriatic arthritis, real-world evidence, observational study, Gynecology and obstetrics, RG1-991, Public aspects of medicine, RA1-1270 |
| الوصف: | Background: Phenotypic features and outcome differences between sexes have been reported in psoriatic arthritis (PsA). However, little is known about sex differences in effectiveness of biologics in clinical practice. Methods: Post hoc gender analysis of the CHRONOS, a multicenter, noninterventional, retroprospective Italian real-world study assessing 6-month and 1-year effectiveness of biologics for PsA. Results: Eligible patients were 399, 43.1% men. Sociodemographic characteristics, type of arthritis, baseline Disease Activity Score 28 joints (DAS28), and duration of biologic treatment were rather homogeneous. More men were overweight/obese and naive to biologics. The most frequently used biologics were TNF-inhibitors and secukinumab in both sexes. DAS28 responders were 72.7% (women) and 70.5% (men) at 6 months, and 68.0% in both sexes at 1 year. American College of Rheumatology (ACR) response showed a trend for men versus women to achieve more frequently ACR50 (32.6% vs. 26.5% at 6 months; 34.9% vs. 20.0% at 1 year) and ACR70 (22.3% vs. 12.4% at 6 months and 25.0% vs. 13.0% at 1 year). Global satisfaction with treatment at enrollment and after 6 months was slightly higher among men [mean (standard deviation) Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9) score: 68.6 (18.6) and 69.9 (18.2), respectively] than women [65.3 (18.2), 66.2 (18.5)]. Conclusions: Overall response to biologics for PsA was rather favorable. With similar baseline disease severity, men appear to have a somewhat earlier and better response with higher treatment satisfaction. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2688-4844 |
| العلاقة: | https://doaj.org/toc/2688-4844Test |
| DOI: | 10.1089/WHR.2021.0063 |
| الوصول الحر: | https://doaj.org/article/8a3b264f81ae436fa03acc92146d2b4bTest |
| رقم الانضمام: | edsdoj.8a3b264f81ae436fa03acc92146d2b4b |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 26884844 |
|---|---|
| DOI: | 10.1089/WHR.2021.0063 |